Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, ...
Healio

Rapid diagnostic test for antibody deficiencies ‘tool to help’ in underserved areas

Please provide your email address to receive an email when new articles are posted on . A prototype point-of-care rapid screening device differentiated between low immunoglobulin G antibody levels ...
EurekAlert!

Reduced infections seen in CLL and NHL patients undergoing immunoglobulin testing and replacement therapy

(WASHINGTON, June 21, 2024) – Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience ...
Healio

Despite benefits, many patients with leukemia, lymphoma do not undergo IgG tests

Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections. Blood cancers increase ...
News Medical

Regular IgG monitoring and replacement therapy reduce severe infections in CLL and NHL patients

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...
The American Journal of Managed Care

Case Report: COVID-19 Risk in CLL Could Be Exacerbated by Hypogammaglobulinemia

The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery. People with chronic lymphocytic leukemia (CLL) are at a higher risk of contracting ...
Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
Seeking Alpha

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...